
PET CT scan and Gamma camera to be commissioned at Tiruchi GH soon
As per a recent work order issued by Tamil Nadu Medical Services Corporation, the project is to be executed by Bengaluru-based company Matrix Imaging Solutions India, under the 'Build, Own and Operate' model of private-public partnership, which will not create any new expenditure for the State Government.
'The successful bidder (service provider) will have to pay 10% of their monthly collection to the Hospital Maintenance Fund for the utilisation of space, water and electricity,' according to the work order.
Experienced specialists and technicians will be recruited by the service provider.
The period of the contract is initially set at five years. 'We have identified a place for the new facility, and since it will emit radiation, stringent precautions will be taken to ensure safety. All the materials used will be approved by the Atomic Energy Regulatory Board (AERB). The facility will be designed according to industrial specifications. 'Hot toilets' will also be built inside the premises. We expect the centre to be ready by the end of this year,' a senior MGMGH official told The Hindu.
He added that two rooms had been earmarked in the Super-Speciality Block of the hospital to provide easy access to patients from private and public hospitals.
According to the initial price list (applicable to all patients), a whole body PET-CT scan will cost ₹11,000. Other scan prices range from ₹9,200 to ₹6,500.
Gamma camera studies will cost ₹1,200 to ₹12,900. Patients covered by the Chief Minister's Comprehensive Health Insurance Scheme will be scanned on cashless mode with requisite authentication.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


News18
an hour ago
- News18
Lupin launches generic medication in US
Agency: PTI Last Updated: New Delhi, Aug 11 (PTI) Drug maker Lupin on Monday said it has launched a medication, used to regulate blood glucose levels, in the US market. The company has launched Glucagon for Injection USP, 1mg/vial packaged in an emergency kit in the US, the Mumbai-based drug maker said in a statement. The company's product is bioequivalent to Eli Lilly and company's Glucagon for Injection, 1 mg/vial, it added. Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus and as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients. As per IQVIA MAT June data, Glucagon for Injection USP, 1mg/vial packaged in an emergency kit had an estimated annual sale of USD 122 million in the US. PTI MSS DRR DRR First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.


Mint
2 hours ago
- Mint
Sukino Healthcare eyes upto ₹250 crore VC boost from Bessemer, Jungle Ventures
MUMBAI : Sukino Healthcare is in talks to raise about ₹200–250 crore from venture capital firms including Bessemer Venture Partners and Jungle Ventures, according to three people familiar with the matter. 'The company has appointed Veda Corporate Advisors to help with the fundraise and the transaction is currently undergoing due diligence," the people said. 'The company has grown well in the last 2 years and has been able to prune costs effectively," one of the people cited above said, adding that the VC firms have issued term sheets. Sukino, Veda, Bessemer and Jungle did not respond to Mint's emails sent on Friday afternoon. This fresh round of funding comes more than two years after the Bengaluru-based healthcare startup raised ₹50 crore in its Series A round from Stakeboat Capital in 2023. At the time, the company earmarked the proceeds for expansion into new geographies and technology-led rehabilitation initiatives. Founded in 2015 by Shalini Menon and Rajinish Menon, the company provides home wound care, IV therapy, and other respiratory rehabilitation services. With a presence in Bengaluru, Kochi and Coimbatore, Sukino's other services include continuum care, neuro, cancer and stroke rehabilitation, hydrotherapy rehab, knee and hip replacement among others. The company's investors also include high-net-worth individuals such as Kris Gopalakrishnan, Mohandas Pai, Bhaskar Pramanik, Arihant Patni, Madusudhan Kela and Krishnan Iyer, according to its website. In FY24, Sukino reported revenue of ₹46 crore, up from ₹38.8 crore in FY23, while narrowing its losses to ₹9.5 crore from ₹15.6 crore a year earlier, per Tracxn data. Market intelligence firm Tracxn lists Athulya Senior Care, Geri Care, and Medwell Ventures as Sukino's competitors. Sector outlook The Indian physical rehab market stood at about $17.1 billion in 2023 and is projected to grow at a CAGR of 15.5% in the next 5 years to reach $35 billion by FY28, according to a Redseer report. Growth is expected to be driven by greater rehab adoption amid low awareness, limited provider availability, and capability constraints, said the report. Redseer also highlighted a major gap in geriatric care: over 40% of the elderly population requires rehab services such as caregiving or assisted living, yet only about 6% currently access such services.


New Indian Express
3 hours ago
- New Indian Express
Experts warn of risks in unsafe plastic surgeries
HYDERABAD: Surgeons emphasised the urgent need for safety in plastic surgeries, noting that negligence could lead to serious complications and infections. This was a key takeaway from the two-day SafePlast-2025 conference, held at T-Hub on August 9 and 10, which saw participation from over 120 plastic surgeons and dermatologists from across India. Speaking at the event, renowned Dubai-based senior plastic surgeon Dr Sanjay Parashar said, 'Plastic and aesthetic surgeries are highly complex. It's important to know how to address issues if they occur and to identify the root cause. Post-treatment infections are a risk, and preventing them is essential, he added. 'Liposuction, cosmetic surgeries, facial corrections (like nose, chin, cheeks), and hair transplants are extremely delicate and must be handled with utmost care, prioritising patient safety.' Dr Gurukarna Vemula, managing director of a plastic surgery centre, said it was important for patients to do a background check of the plastic surgeons they would visit for treatment. He cautioned that 'many problems arise when untrained practitioners perform such treatments. Some hair transplant patients develop scalp infections; Botox, fillers, and laser treatments can also have side effects. To avoid these, patients must choose the right doctor.'